FDA Home Page | Search FDA Site | A-Z Index | Contact FDA

DOCKETS MANAGEMENT

Dockets Entered On June 3, 2003 TABLE OF CONTENTS
Docket #			Title
1975N-0183H	Health-Care Antiseptic Drug Products for OTC Human Use
1981N-0033P	Antiplaque & Antiplaque-Related Claims
1994P-0036	Req labeling of trans fatty acid & prohibit deceptive claims
1999D-0674	Investigational new drug applications for phase 2&3 of drugs
2000N-1396	Bioengineered Foods Consumed By Humans or Animals
2001D-0224	Mass Spectrometry for Confirmation of Identity of Animal Drug Residues
2003D-0197	Guidance for Industry on Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate -- Labeling Enforcement Policy; Availability
2003N-0034	FDA Safety Alert/ Public Health Advisory Readership Survey
2003P-0196	Switch Nicotrol Inhaler (nicotine Inhalation System) From Prescription to Over the Counter Status
2003P-0216	ANDA for a drug product(1.5 mg levonorgestrel tablet) in strength(Plan B 0.75 mg Levonorgestrel tablet) in strength
2003P-0217	Concept of shared exclusivity for multiple ANDA submitted on the same day
DETAILS
1975N-0183H		Health-Care Antiseptic Drug Products for OTC Human Use
NPR 2		FDA			Vol #:		149
1981N-0033P		Antiplaque & Antiplaque-Related Claims
BKG 2		Background Material (Refs 1-467)			Vol #:		13
NAP 1		FDA			Vol #:		12
1994P-0036		Req labeling of trans fatty acid & prohibit deceptive claims
ACK 2		HFA-305 to Bantransfats.com			Vol #:		72
CP 2		Bantransfats.com			Vol #:		72
1999D-0674		Investigational new drug applications for phase 2&3 of drugs
GDL 2		GUIDANCE			Vol #:		1
NAD 2		FDA			Vol #:		1
2000N-1396		Bioengineered Foods Consumed By Humans or Animals
EMC 11563		PJ Perkins			Vol #:		349
EMC 11564		Jackie and Chris Stover			Vol #:		349
2001D-0224		Mass Spectrometry for Confirmation of Identity of Animal Drug Residues
GDL 2		GUIDANCE			Vol #:		1
NAD 2		FDA			Vol #:		1
2003D-0197		Guidance for Industry on Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate -- Labeling Enforcement Policy; Availability
GDL 1	GUIDANCE			Vol #:		1
NAD 1	FDA			Vol #:		1
2003N-0034	FDA Safety Alert/ Public Health Advisory Readership Survey
N 2	FDA			Vol #:		1
2003P-0196	Switch Nicotrol Inhaler (nicotine Inhalation System) From Prescription to Over the Counter Status
ACK 1	HFA-305 to Pharmacists Planning Services, inc.			Vol #:		1
2003P-0216	ANDA for a drug product(1.5 mg levonorgestrel tablet) in strength(Plan B 0.75 mg Levonorgestrel tablet) in strength
ACK 1	HFA-305 to HRA PHARMA			Vol #:		1
2003P-0217	Concept of shared exclusivity for multiple ANDA submitted on the same day
ACK 1	HFA-305 to Venable, Baeitjer, Howard & Civiletti			Vol #:		1

Dockets Home | Accessibility | Dockets Contacts and Location | Operating Status | Item Codes